TP53 and exocrine pancreatic carcinoma: Chemosensitivity studies havebeen conducted against human pancreatic carcinoma (MIA PaCa-2), humancolorectal adenocarcinoma p53-wildtype (HCT116 p53+/+) and normal human retinal epithelial celllines (APRE-19).